伊莱克斯阿斯普雷拉多糖通过抗氧化,抗炎和肠道微生物群调节效应减轻肝损伤

相关实验视频

Updated: May 22, 2025

08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

799

Yao Wang¹, Lijing Ye¹, Ruikun Yan¹

¹The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, China.

International journal of biological macromolecules

|March 13, 2025

概括

伊莱克斯阿斯普雷拉多糖 (IAP) 通过减少氧化应激和炎症来保护肝脏. 这项研究表明,IAP通过调节肠道微生物群和抑制有害细菌来改善肝脏健康.

科学领域:

药理学药理学是指药理学的学科.
肝病学肝病学是一种肝病学.
微生物学微生物学

背景情况:

伊莱克斯·阿斯普雷拉 (Ilex asprella) 传统上用于医疗目的,特别是保护肝脏.
来自Ilex asprella (IAP) 的多糖是具有尚未探索的生物活动的关键活性成分.
了解IAP对肝损伤的影响对于其治疗应用至关重要.

研究的目的:

在体内研究伊莱克斯阿斯普雷拉多糖 (IAP) 对肝损伤的预防作用.
阐明IAP肝脏保护作用的潜在机制,包括抗氧化,抗炎和微生物群调节作用.

主要方法:

H&E和TUNEL染色以评估肝脏组织形态学和亡.
测量抗氧化能力的生物化学分析 (SOD,T-AOC,GSH-Px).
西部斑点分析用于调查信号通路 (Nrf2/HO-1,TLR4/NF-κB,MAPK).
16S RNA测序以分析肠道微生物群的组成.

主要成果:

IAP改善了D-GalN/LPS诱导的肝损伤,减少了他的病理变化和亡.
IAP通过Nrf2/HO-1通路增强了抗氧化能力并抑制了氧化应激.
IAP通过降低促炎性细胞因子 (IL-6,IL-1β,TNF-α) 和抑制TLR4/NF-κB和MAPK信号传递,显示出抗炎作用.
IAP重新调节肠道微生物群,减少有害细菌和增加有益的益生菌.

结论:

伊莱克斯阿斯普雷拉多糖 (IAP) 对抗肝损伤具有显著的肝保护作用.
IAP通过减轻氧化应激,抑制炎症和调节肠道微生物群组成来起作用.
这些发现支持IAP作为肝脏保护治疗剂的潜力.

关键词:

抗炎药物抗炎药物抗炎药物我们的肠道微生物群.肝脏受伤肝脏受伤它是一种多糖化合物.

相关概念视频

01:17

Drugs for Treatment of Diarrhea-Predominant IBS

133

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

133

01:29

Drugs for Treatment of Ulcerative Colitis in IBD

115

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

115

01:21

Drugs for Treatment of Constipation-Predominant IBS

124

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

124

01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

01:17

Irritable Bowel Syndrome I: Introduction

213

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

213

01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

106

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

106